Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huachuan Baolie Granules is a traditional Chinese medicine (TCM) developed by Guizhou Weimen Pharmaceutical for the treatment of chronic prostatitis. The formulation is specifically indicated for patients presenting with the TCM syndrome of damp-heat downward flow and qi-blood stasis. The drug is likely derived from the medicinal herb *Polygonum capitatum* (locally known in Guizhou as 'Huachuan'), which is recognized for its anti-inflammatory, antimicrobial, and analgesic properties. Clinical development, including the Phase 2 trial CTR20131507, has focused on evaluating its efficacy and safety in alleviating pelvic pain and urinary dysfunction by clearing heat, inducing diuresis, and promoting blood circulation to resolve stasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huachuan Baolie Granules.